Teva Upbeat On Risperidone Results
Collaborating With MedinCell On Long-Acting Injectable Version
Following positive trial results, Teva says it is exploring options with the US FDA for filing a long-acting subcutaneous injectable version of risperidone that it is developing with MedinCell.
You may also be interested in...
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.